Under construction – not a live service
Sign in

2022-501876-24-00RecruitingPhase 1

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Aug 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
54 (estimated)
First submitted
16 Feb 2023
Start date
17 Jun 2022
Lead sponsor
F. Hoffmann-La Roche AG
EU CT number
2022-501876-24-00
EudraCT number
2021-000846-16

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 54
  • 13 sites in 5 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Sites (13)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
University Hospital AugsburgAugsburgGermanyRecruiting
Universitaetsklinikum Ulm AoRUlmGermanyRecruiting
Hospital Universitari Vall d'HebronBarcelonaSpainRecruiting
Hospital de la Santa Creu i Sant PauBarcelonaSpainRecruiting
University Hospital Of Clermont-FerrandClermont-FerrandFranceCompleted
Institut Claudius RegaudToulouseFranceCompleted
Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBresciaItalyRecruiting
Ospedale San Raffaele S.r.l.MilanItalyRecruiting
ASST Grande Ospedale Metropolitano NiguardaMilanItalyRecruiting
Hospital Santa Maria Della MisericordiaPerugiaItalyRecruiting
Pratia S.A.CracowPolandRecruiting
Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych FazGdanskPolandRecruiting
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclawPolandRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.